Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

New recombinant head shock proteins developed at Alternative Innovative Technologies

Feb. 1, 2013

Mesoblast cleared to begin study of mesenchymal precursor cells in patients with RA

Jan. 31, 2013

Merck Serono and Feinstein Institute enter partnership

Jan. 31, 2013

Olatec begins phase II trial of OLT-1177

Jan. 23, 2013

Novartis receives positive CHMP opinion for Ilaris in acute gouty arthritis

Jan. 22, 2013

Phase II trial of NeoFuse stem cell product meets endpoints

Jan. 14, 2013

Researchers at CSL disclose new G-CSF-R antibodies

Jan. 9, 2013

Janssen Pharmaceutica divulges new MMP inhibitors

Dec. 31, 2012

Daiichi Sankyo patents new tyrosine-protein kinase inhibitors

Dec. 31, 2012

Japanese MHLW approves marketing application for Cimzia in RA

Dec. 28, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...